Drugs / BAT3306
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07180862 | Oct 2025 → Feb 2027 expected | non-small cell lung carcinoma | Bio-Thera Solutions | Recruiting | No outcome recorded |
| Phase 1 | NCT06111196 | Nov 2023 → Jun 2024 | — | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06280196 | Jul 2024 → Jul 2025 | non-small cell lung carcinoma | Bio-Thera Solutions | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT3306 | “BAT3306 injection” NCT06111196 ↗ |
| Action | Inhibit | “Anti-PD-1” NCT06111196 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection” NCT06111196 ↗ |
| Route | Intravenous | “intravenous injection” NCT06111196 ↗ |